Primary primitive neuroectodermal tumor of the urinary bladder: a case report

Yasuyuki Kobayashi, Kenji Nishimura, Taigo Kato, Hidefumi Kishikawa, Yasuji Ichikawa

Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan

Correspondence: Yasuyuki Kobayashi. Address: Department of Urology, Hyogo Prefectural Nishinomiya Hospital Rokutanji-cho, Nishinomiya city, Japan. Telephone: 81-798-345-151. Fax: 81-798-235-151. E-mail: ya_su_koba@yahoo.co.jp

Received: May 17, 2012
Accepted: July 23, 2012
Published: August 1, 2012
DOI: 10.5430/jst.v2n4p53
URL: http://dx.doi.org/10.5430/jst.v2n4p53

Abstract

We report a rare case of primary primitive neuroectodermal tumor (PNET) of the urinary bladder. An 85-year-old man with hormone refractory prostate cancer was presented with gross hematuria. Abdominal computed tomography showed a tumor occupying the right lateral portion and neck of the bladder wall, while a cystoscopic examination revealed a bleeding, sessile globular tumor with no papillary features. Transurethral resection of the bladder tumor was performed. Histopathological results showed a small round cell tumor forming rosettes, further positive immunoreactivities for some neural markers and MIC gene product (CD99), which indicated PNET of the bladder. Four months after surgery, PNET of the bladder recurred with rapid growth and the patient died of tumor. To our knowledge, there have been only 8 such cases reported.

Key words

Primitive neuroectodermal tumor (PNET), Urinary bladder

1 Introduction

A primitive neuroectodermal tumor (PNET) is a malignant small round blue-cell tumor exhibiting a variable degree of neural differentiation, which arises outside the brain, spinal cord, and sympathetic nervous system [1]. In general, a PNET is a very aggressive tumor with rapid local infiltration combined with widespread metastasis [2,3]. Its aggressive behavior is reflected by a low 5-year survival rate ranging from 60 to 90% when treated with surgical resection in combination with radiochemotherapy [3]. Recently such rare tumors with a highly malignant potential have been increasingly reported in various organs, including kidney [3] and prostate [4] in the field of urology. PNET of the urinary bladder is extremely rare, with only 8 cases previously reported to our knowledge. Herein, we present an additional case of a patient and review previously published reports.

2 Case presentation

An 85-year-old man with hormone refractory prostate cancer (HRPC) (poorly differentiated adenocarcinoma, Gleason score 10, clinical stage T3bN0M1b) was presented with gross hematuria. Urinary cytology findings were positive.
Abdominal computed tomography showed a tumor occupying the right lateral portion and neck of the bladder wall, without evidence of an extravesical tumor or lymph node swelling (Figure 1a). A cystoscopic examination revealed a bleeding, sessile globular tumor with no papillary features. Chest X-ray findings showed no lung metastasis. The patient underwent transurethral resection of the bladder tumor (TURBT). Histologically, the tumor was composed of small round blue malignant cells without differentiation and with an intervening thin fibrovascular stroma (Figure 2a). The loosely cohesive tumor cells had scant levels of basophilic cytoplasm and highly polymorphic nuclei, with occasional rosette structures (Figure 2b). Immunohistochemical findings showed that the tumor cells were positive for the neural markers vimentin, neuron-specific enolase (NSE) (Figure 2c), and S-100 protein, while periodic acid-Schiff (PAS) staining showed the presence of glycogen. The stains for prostate specific antigen (PSA), α-methylacyl-CoA Racemase (P504S), leucocyte common antigen, desmin, α-smooth muscle actin, and cytokeratin 7 were negative. Furthermore, the tumor cells showed a significant reactivity for the MIC2 gene product (CD99) (Figure 2d). From these findings, the histological diagnosis was PNET of the bladder. No further treatment was initiated in consideration of the advanced age of the patient and HRPC terminal stage. Four months after TURBT, PNET of the bladder recurred (cystoscopic findings shown in Figure 1b) accompanied by rapid tumor growth, and the patient died of tumor metastasis. No autopsy was performed.

Figure 1.

a. Abdominal computed tomography showed a tumor occupying the right lateral portion and neck of the bladder wall.

b. A cystoscopic examination revealed a bleeding, sessile globular tumor in the bladder neck with no papillary features.

Figure 2. Histology of PNET of the urinary bladder

a. Sheets of small round blue-cell tumors without differentiation (H & E);

b. High-power magnification of rosettes (arrows) (H & E);

c. The tumor cells were positive for the neuron-specific enolase (NSE);

d. The tumor cells were positive for the MIC2 gene product (CD99).
3 Discussion

A PNET of the urinary bladder is extremely rare, with only 8 cases previously reported. A review of those previous reports including the present case is shown in Table 1. The affected patients were 5 men and 4 women, with a mean age of 50.7 years old (range, 15-85). Five suffered from gross hematuria. Surgical treatment was performed in 8 of 9 cases (total cystectomy in 3, partial cystectomy in 1, TURBT only in 4). Adjuvant chemotherapy was performed in 2 of 3 total cystectomy cases, and those patients remained free of disease at follow-up examinations performed at 18 months and 3 years, respectively. In contrast, 3 of 4 patients treated by TURBT showed rapid recurrence and thereafter died of tumor. Therefore, a total cystectomy with adjuvant chemotherapy seems to provide long-term survival for PNET of the urinary bladder. The recommended chemotherapy regimen consists of vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide [5, 6].

Table 1. Reported cases of primary neuroectodermal tumor of the bladder

<table>
<thead>
<tr>
<th>No</th>
<th>Author (Journal)</th>
<th>Age/sex</th>
<th>Chief complaint</th>
<th>Therapy</th>
<th>Follow-up</th>
<th>Immunohistochemical study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CD99</td>
</tr>
<tr>
<td>1</td>
<td>Banerjee SS (Histopathology, 1997)</td>
<td>21/M</td>
<td>Microscopic hematuria</td>
<td>Total cystectomy chemotherapy</td>
<td>NED: 18months</td>
<td>(++) (-) (+) (+/-) (-)</td>
</tr>
<tr>
<td>2</td>
<td>Angelo E (J Urol, 1997)</td>
<td>15/F</td>
<td>Gross hematuria</td>
<td>Partial cystectomy chemotherapy</td>
<td>NA</td>
<td>(++) (-) (+) (+/-) NA</td>
</tr>
<tr>
<td>3</td>
<td>Mentzel T (Pathologe, 1998)</td>
<td>62/M</td>
<td>High fever attack</td>
<td>TURBT</td>
<td>DOC: 3weeks</td>
<td>(++) (+/-) (-) (+) (+/-) (-)</td>
</tr>
<tr>
<td>4</td>
<td>Desai S (Histopathology, 1998)</td>
<td>38/F</td>
<td>Gross hematuria</td>
<td>Total cystectomy</td>
<td>NA</td>
<td>(++) (-) (+) (+++) (-)</td>
</tr>
<tr>
<td>5</td>
<td>Mentzel T (Pathologe, 1998)</td>
<td>61/F</td>
<td>NA</td>
<td>No treatment</td>
<td>NA</td>
<td>(++) (-) (+) NA (-)</td>
</tr>
<tr>
<td>6</td>
<td>Mentzel T (Pathology, 2003)</td>
<td>81/M</td>
<td>Urge incontinence</td>
<td>TURBT</td>
<td>DOD: 2weeks</td>
<td>(++) (-) (+) (+++) (-)</td>
</tr>
<tr>
<td>7</td>
<td>Lopez-Beltran A (J Clin Pathol, 2006)</td>
<td>21/F</td>
<td>Gross hematuria</td>
<td>Total cystectomy chemotherapy</td>
<td>NED: 3years</td>
<td>(++) (+/-) (-) (+) (-) (+/-)</td>
</tr>
<tr>
<td>8</td>
<td>Elinger J (Urology, 2006)</td>
<td>72/M</td>
<td>Gross hematuria</td>
<td>TURBT</td>
<td>NA</td>
<td>(++) NA (+) NA NA</td>
</tr>
<tr>
<td>9</td>
<td>Our case</td>
<td>85/M</td>
<td>Gross hematuria</td>
<td>TURBT</td>
<td>DOD: 3months</td>
<td>(++) (+) (+) (+) (-)</td>
</tr>
</tbody>
</table>

NA: not available, TURBT: transurethral resection of the bladder tumor; NED: no evidence of disease; DOC: dead of other causes; DOD: dead of disease; PAS: periodic acid -Schiff; NSE: neuron-specific enolase; CK: cytokeratin.

The present diagnosis of PNET was established by histological and immunohistochemical analyses. Histologically, PNET is a malignant small round blue-cell tumor that exhibits a variable degree of neural differentiation, though all points on the spectrum share a predominantly lobular growth pattern [7]. For immunohistochemistry analysis, the most useful neural markers are NSE, vimentin, S-100, and synaptophysin, with staining detectable in up to 60% of the cases [8]. Further, the tumor cells show a strong expression of MIC-2 protein (CD99) [9]. In order to qualify for the designation of PNET, it is suggested that the tumor must show rosettes and be positive for at least two of the neural markers [7]. The detection of EWS-FLI1 type I fusion also allows us to exclude difficult differential diagnoses that cannot be separated.
immunohistochemically [10]. In the present case, positive staining for neural markers and CD99 was helpful for the diagnosis of PNET. Moreover, the lack of staining of muscle, lymphoid or neuroendocrine markers excludes rhabdomyosarcoma, lymphoma, and neuroendocrine carcinoma.

In the present case, a cystoscopic examination revealed a bleeding, sessile globular tumor with no papillary features, which are different features from those of a papillary tumor such as a common urinary transitional cell carcinoma. Initially, we clinically diagnosed the mass as a prostatic urethral tumor with bladder neck invasion from prostate cancer, because of the tumor appearance and the HRPC terminal condition of the patient. However, the histopathological finding was PNET of the urinary bladder that did not originate from the prostate gland as proved by the lack of staining of PSA and P504S. In the report of Gousse [6], no papillary features of this kind of tumor are demonstrated in a cystoscopic examination. Thus, when no papillary tumor is discovered by cystoscopy, it is necessary to take PNET of the bladder into consideration as a differential diagnosis.

In conclusion, we report the 9th known case of PNET of the urinary bladder. Diagnosis of this type of tumor and effective therapy must be conducted as soon as possible because of its highly malignant potential.

Acknowledgements
I would like to express my gratitude to all those who gave me the possibility to complete this work. I want to thank Department of Pathology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan for giving me valuable advice.

References